Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Gynecologic 1Endocrine 1

Conditions

Ovarian Neoplasms 104Fallopian Tube Neoplasms 47Carcinoma, Ovarian Epithelial 27Neoplasms 12Breast Neoplasms 7Neoplasm Metastasis 5Recurrence 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Peritoneal Neoplasms 3Ovarian Cancer Recurrent 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Multiple Myeloma 2Lung Neoplasms 2Disease Progression 2Colorectal Neoplasms 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vaginal Neoplasms 1Vaccinia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sezary Syndrome 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1

Interventions

pembrolizumab 2belinostat 2taxane 1liposomal doxorubicin 1Vinorelbine 1RRx-001 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1Molecular Diagnostic Techniques 1Irinotecan 1Immunotherapy 1Gemcitabine 1Fluorouracil 1Etoposide 1Drug Therapy 1Cisplatin 1Carboplatin 1Biological Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × liposomal doxorubicin × Gynecologic × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡